StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Reaktion

Dimethylformamide → 7-[4-(2-propoxyethoxy)phenyl]-2,3-dihydro-1H-1-benzazepine-4-carboxamide

HRID 587077
Drucken

Reaktionsgleichung

Reaktionsgleichung von HRID 587077
C(OCCC[N:7]1[C:13]2[CH:14]=[CH:15][C:16]([C:18]3[CH:23]=[CH:22][C:21]([O:24][CH2:25][CH2:26][O:27][CH2:28][CH2:29][CH3:30])=[CH:20][CH:19]=3)=[CH:17][C:12]=2[CH:11]=[C:10]([C:31](O)=[O:32])[CH2:9][CH2:8]1)C.S(Cl)(Cl)=O.C[N:39](C=O)C>C1COCC1>[CH2:28]([O:27][CH2:26][CH2:25][O:24][C:21]1[CH:22]=[CH:23][C:18]([C:16]2[CH:15]=[CH:14][C:13]3[NH:7][CH2:8][CH2:9][C:10]([C:31]([NH2:39])=[O:32])=[CH:11][C:12]=3[CH:17]=2)=[CH:19][CH:20]=1)[CH2:29][CH3:30]
KomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion

Komponenten

5

Edukt 3

HCID 6228DimethylformamideHCID 24386Thionyl ChlorideHCID 223289901-(3-ethoxypropyl)-7-[4-(2-propoxyethoxy)phenyl]-2,3-dihydro-1H-1-benzazepine-4-carboxylic acid

Produkt 1

HCID 867598407-[4-(2-propoxyethoxy)phenyl]-2,3-dihydro-1H-1-benzazepine-4-carboxamide

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 8028
Tetrahydrofuran
Lösungsmittel

Versuchsvorschrift

To a solution of 1-(3-ethoxypropyl)-7-[4-(2-propoxyethoxy)phenyl]-2,3-dihydro-1H-1-benzazepine-4-carboxylic acid (250 mg) in THF (10 ml) were added thionyl chloride (0.080 ml) and DMF (one droplet) at room temperature, and the mixture was stirred for 1.5 hours. The solvent was evaporated under reduced pressure, and the resulting residue was dissolved in THF (20 ml), which was added dropwise to a solution of 4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]aniline (133 mg) and triethylamine (0.46 ml) in THF (3 ml) at 0° C. The mixture was stirred at room temperature for 2.5 hours, water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, and dried with magnesium sulfate. After concentration under reduced pressure, the residue was purified with column chromatography (ethanol:ethyl acetate=1:9→1:3), and the resulting crystals were purified by recrystallization (hexane-ethyl acetate) to give 1-(3-ethoxypropyl)-N-[4-[[N-methyl-N-tetrahydropyran-4-yl)amino]methyl]phenyl]-7-[4-(2-propoxyethoxy)phenyl]-2,3-dihydro-1H-1-benzazepine-4-carboxamide (Compound 105) (242 mg) as yellow crystals.

Aufarbeitung

  1. customThe solvent was evaporated under reduced pressure
  2. dissolutionthe resulting residue was dissolved in THF (20 ml)
  3. additionwhich was added dropwise to a solution of 4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]aniline (133 mg) and triethylamine (0.46 ml) in THF (3 ml) at 0° C
  4. stirringThe mixture was stirred at room temperature for 2.5 hours
  5. additionwater was added
  6. extractionthe mixture was extracted with ethyl acetate
  7. washThe organic layer was washed with saturated brine
  8. dry with materialdried with magnesium sulfate
  9. concentrationAfter concentration under reduced pressure
  10. customthe residue was purified with column chromatography (ethanol:ethyl acetate=1:9→1:3)
  11. customthe resulting crystals were purified by recrystallization (hexane-ethyl acetate)

Quellen und Nachweise

ORD-Eintrag
ord-ce052b7fb2634322b7b52fed79fcc916
Quelldatensatz
uspto-grants-2005_08
DOI
10.6084/m9.figshare.5104873.v1
Patentnummer
US06936602B1

Notizen zur Reaktion

Auf dieser SeiteKomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion